LM-108 with immunotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have triple-negative breast cancer that cannot be removed by surgery, has spread to other parts of the body, or has come back after treatment.
- You are in relatively good health (able to care for yourself and out of bed more than half the day).
- You have at least one tumor that can be measured on scans.
- You have adequate organ function (heart, liver, kidneys, and bone marrow) as shown by blood tests.
- You are willing to provide a fresh tissue sample from your tumor before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests adding toripalimab (an immunotherapy drug) to chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a new combination of two drugs (Sac-TMT and Toripalimab) as the first treatment for women with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see if this combination can shrink or control the cancer better than standard treatments.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.